GAVI board requests analysis for future vaccine decisions

The board of the GAVI Alliance asked on Wednesday for analysis that will inform the organization's decisions on its vaccines portfolio and a long-term strategy for supporting the introduction of inactivated polio vaccine.

The board asked for further research to determine the potential impact vaccines could have in five disease areas being considered for future support, including rabies, malaria, cholera, yellow fever and influenza in pregnant women. The decision to request further analysis on potential additions to GAVI's portfolio resulted from initial assessment of the possible effect of interventions on a range of diseases considered to be life-threatening.

GAVI's board also considered the user-friendliness of the vaccines, how much they might aid in outbreak prevention and their ability to benefit vulnerable groups.

Final decisions on which vaccines might be added to the portfolio are planned for the board's November meeting.

The board also agreed that the GAVI Alliance should be a leader in introducing inactivated polio vaccine into partner countries as part of the Polio Eradication Endgame Strategic Plan. The board requested that the GAVI secretariat present a long-term strategy in support of the role GAVI would play in relation to IPV. The report will also be presented at the November meeting.

GAVI's board called on donors to urgently clarify the use of Polio Eradication Endgame funds to make sure the cost of implementing IPV would not negatively impact GAVI's current strategic objectives.